Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 46Squamous Cell Carcinoma of Head and Neck 23Carcinoma, Non-Small-Cell Lung 21Colonic Neoplasms 13Head and Neck Neoplasms 10Rectal Neoplasms 9Neoplasms 9Neoplasm Metastasis 9Lung Neoplasms 8Pancreatic Neoplasms 7Carcinoma, Squamous Cell 6Mouth Neoplasms 5Carcinoma 5Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Thyroid Neoplasms 3Solid Tumors 3Oropharyngeal Neoplasms 3Gastrointestinal Neoplasms 3Carcinoma, Pancreatic Ductal 3Breast Neoplasms 3Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Laryngeal Diseases 2Endometrial Neoplasms 2mCRC 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

Oxaliplatin 13Fluorouracil 13pembrolizumab 12Paclitaxel 11Leucovorin 10Radiotherapy 8Nivolumab 8Drug Therapy 7Cisplatin 7Carboplatin 7Capecitabine 7Esophagectomy 6Trastuzumab 5Specimen Handling 5Radiation 5Taxes 4Irinotecan 4trastuzumab deruxtecan 3patritumab deruxtecan 3Surgical Procedures, Operative 3Radiotherapy, Intensity-Modulated 3Immunotherapy 3zanidatamab 2relatlimab 2durvalumab 2atezolizumab 2TP protocol 2Surveys and Questionnaires 2Ramucirumab 2Proton Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Cetuximab × 90 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡